ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.653,80
-0,08%
S&P 500
5.305,10
-0,06%
US Dollar vs BRL
5,09803
-0,13%
Bitcoin
71.158,82
-0,41%
Brent Oil
82,875
-0,78%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Kronos Bio Inc (KRON)

  7. Kronos Bio Inc (KRON) Notícias

KRON

Kronos Bio (KRON)

Kronos Bio Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:KRON
DataHoraFonteTítuloCódigoCompanhia
21/05/202409:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
21/05/202409:15GlobeNewswire Inc.Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer NASDAQ:KRONKronos Bio Inc
09/05/202417:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRONKronos Bio Inc
09/05/202417:05GlobeNewswire Inc.Kronos Bio Reports First-Quarter 2024 Financial ResultsNASDAQ:KRONKronos Bio Inc
24/04/202417:01GlobeNewswire Inc.Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:KRONKronos Bio Inc
21/03/202408:05GlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
07/03/202418:05GlobeNewswire Inc.Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash RunwayNASDAQ:KRONKronos Bio Inc
05/03/202418:44GlobeNewswire Inc.Kronos Bio To Present Three Posters at AACR 2024 Annual MeetingNASDAQ:KRONKronos Bio Inc
27/02/202418:05GlobeNewswire Inc.Kronos Bio Announces Participation in 44th Annual Cowen Health Care ConferenceNASDAQ:KRONKronos Bio Inc
23/02/202422:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
23/02/202422:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
18/12/202318:06GlobeNewswire Inc.Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development CandidateNASDAQ:KRONKronos Bio Inc
04/12/202310:00GlobeNewswire Inc.Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:KRONKronos Bio Inc
27/11/202318:05GlobeNewswire Inc.Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:KRONKronos Bio Inc
13/11/202318:05GlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
02/11/202317:05GlobeNewswire Inc.Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 StudyNASDAQ:KRONKronos Bio Inc
02/11/202313:00GlobeNewswire Inc.Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual MeetingNASDAQ:KRONKronos Bio Inc
27/10/202309:00GlobeNewswire Inc.Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual MeetingNASDAQ:KRONKronos Bio Inc
13/10/202313:30GlobeNewswire Inc.Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTCNASDAQ:KRONKronos Bio Inc
04/10/202317:05GlobeNewswire Inc.Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13NASDAQ:KRONKronos Bio Inc
17/08/202309:00GlobeNewswire Inc.Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate DevelopmentNASDAQ:KRONKronos Bio Inc
08/08/202317:05GlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
26/06/202318:19Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KRONKronos Bio Inc
26/06/202317:16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KRONKronos Bio Inc
06/06/202309:00GlobeNewswire Inc.Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality AssuranceNASDAQ:KRONKronos Bio Inc
01/06/202317:05GlobeNewswire Inc.Kronos Bio Announces Participation in Upcoming Investor ConferencesNASDAQ:KRONKronos Bio Inc
30/05/202317:36Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:KRONKronos Bio Inc
10/05/202317:05GlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
27/04/202317:36Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:KRONKronos Bio Inc
24/04/202317:21Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:KRONKronos Bio Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:KRON

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HAGA3
HAGA ON
BOV
PRIO3
PETRORIO ON
BOV
PDGR3
PDG REALT ON
BOV
SGPS3
SPRINGS ON
BOV
INBR32
Inter &
BOV
COGN3
COGNA ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
GOLL4
GOL PN
BOV
LUPA3
LUPATECH ON
BOV
CMIG4
CEMIG PN
BOV
CASH3
Meliuz S.A ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
LWSA3
LOCAWEB ON
BOV
HOOT4
HOTEIS OTHON PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados